Abstract
Hematopoietic Progenitor Cell (HPC) Apheresis generally results in a mononuclear cell product that is highly enriched for hematopoietic stem and progenitor cells when performed on autologous patients in whom autologous stem cell transplant is planned who have been mobilized with cytotoxic chemotherapy and exogenous hematopoietic growth factors (cytokines) and possibly CXCR4 antagonists. Alternatively, patients scheduled for autologous transplants may be mobilized with cytokines only or a combination of cytokines and CXCR4 antagonists. Allogeneic Donors, either matched related donors (MRD) or matched unrelated donors (MUD), are typically mobilized with cytokines only. The HPC Apheresis product, enriched for hematopoietic progenitor cells collected from the patient/donor’s peripheral blood via an apheresis system, is used for restoring hematopoiesis in the patient/recipient who has received myeloablative therapy. Timing of the collection of an HPC Apheresis product from allogeneic donors is based on the schedule of the recipient’s myeloablative regime. However, the optimal timing of collection on HPC Apheresis product from a patient scheduled for an autologous stem cell transplant can be complex.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Moog R (2006) Mobilization and harvesting of peripheral blood stem cells. Curr Stem Cell Res Ther 1:189–201
Pusic I, DiPersio JF (2008) The use of growth factors in hematopoietic stem cell transplantation. Curr Pharm Des 14:1950–1961
Traynor K (2009) Plerixafor approved for autologous hematopoietic stem-cell transplantation. Am J Health Syst Pharm 66:112
Cashen A, Lopez S, Gao F et al (2008) A phase II study of plerixafor (AMD3100) plus G-CSF for autologous hematopoietic progenitor cell mobilization in patients with Hodgkin lymphoma. Biol Blood Marrow Transplant 14:1253–1261
DiPersio JF, Micallef IN, Stiff PJ et al (2009) Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin’s lymphoma. J Clin Oncol 27:4767–4773
DiPersio JF, Stadtmauer EA, Nademanee A et al (2009) Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood 113:5720–5726
McLeod BC, Price TH, Weinstein R (2003) Apheresis: principles and practice, 2nd edn. AABB Press, Bethesda, MA, pp 508–510
Mozobil™ (plerixafor injection) Prescribing Information. Genzyme Corporation
Operators Manual for SYSMEX XE-2100L. Sysmex America Corporation. Mundelein, Illinois, USA
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2012 Springer Science+Business Media, LLC
About this protocol
Cite this protocol
Vaughn, M.L., Waller, E.K. (2012). Monitoring Blood for CD34+ Cells to Determine Timing of Hematopoietic Progenitor Cells Apheresis. In: Kolonin, M., Simmons, P. (eds) Stem Cell Mobilization. Methods in Molecular Biology, vol 904. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-61779-943-3_6
Download citation
DOI: https://doi.org/10.1007/978-1-61779-943-3_6
Published:
Publisher Name: Humana Press, Totowa, NJ
Print ISBN: 978-1-61779-942-6
Online ISBN: 978-1-61779-943-3
eBook Packages: Springer Protocols